Get the Stockscreener App
764.71
2.21%
16.52
Pre-market:
769.50
4.79
+0.63%
Overview
News
Price History
Option Chain
Financials
Why LLY Down?
Discussions
Forecast
Stock Split
Dividend History
Lilly Eli Co stock is traded at $764.71, with a volume of 3.87M.
It is up +2.21% in the last 24 hours and up +9.05% over the past month.
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
See More
Previous Close:
$748.19
Open:
$745.405
24h Volume:
3.87M
Relative Volume:
0.91
Market Cap:
$723.76B
Revenue:
$53.26B
Net Income/Loss:
$13.80B
P/E Ratio:
49.98
EPS:
15.3
Net Cash Flow:
$-50.20M
1W Performance:
+1.88%
1M Performance:
+9.05%
6M Performance:
-6.00%
1Y Performance:
-17.20%
1-Day Range:
$744.54
$770.38
1-Week Range:
$742.11
$770.38
52-Week Range:
$623.78
$939.86
Lilly Eli Co Stock (LLY) Company Profile
Name
Lilly Eli Co
Sector
Industry
Phone
(317) 276-2000
Address
LILLY CORPORATE CTR, INDIANAPOLIS, IN
Compare LLY with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LLY
Lilly Eli Co
|
764.71 | 670.72B | 53.26B | 13.80B | -50.20M | 15.30 |
|
JNJ
Johnson Johnson
|
176.46 | 427.24B | 90.62B | 22.66B | 18.18B | 9.35 |
|
ABBV
Abbvie Inc
|
216.26 | 384.42B | 58.33B | 3.73B | 18.24B | 2.10 |
|
NVS
Novartis Ag Adr
|
122.78 | 238.71B | 53.40B | 13.68B | 16.89B | 6.9231 |
|
MRK
Merck Co Inc
|
81.09 | 202.37B | 63.43B | 16.42B | 14.72B | 6.49 |
Lilly Eli Co Stock (LLY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-27-25 | Upgrade | HSBC Securities | Reduce → Hold |
| Aug-18-25 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Aug-07-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Jun-05-25 | Downgrade | Erste Group | Buy → Hold |
| Apr-28-25 | Downgrade | HSBC Securities | Buy → Reduce |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-10-24 | Resumed | BofA Securities | Buy |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Oct-17-24 | Initiated | Bernstein | Outperform |
| Sep-13-24 | Resumed | Citigroup | Buy |
| Aug-12-24 | Upgrade | Deutsche Bank | Hold → Buy |
| Feb-21-24 | Downgrade | DZ Bank | Buy → Hold |
| Feb-16-24 | Reiterated | Morgan Stanley | Overweight |
| Dec-21-23 | Downgrade | Daiwa Securities | Buy → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Oct-20-23 | Resumed | UBS | Buy |
| Aug-09-23 | Upgrade | Jefferies | Hold → Buy |
| Jul-26-23 | Reiterated | Citigroup | Buy |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| May-24-23 | Reiterated | BofA Securities | Buy |
| May-24-23 | Reiterated | UBS | Buy |
| Mar-13-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Mar-06-23 | Initiated | Jefferies | Hold |
| Feb-15-23 | Downgrade | Societe Generale | Hold → Sell |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| Sep-22-22 | Upgrade | UBS | Neutral → Buy |
| May-23-22 | Initiated | SVB Leerink | Outperform |
| Apr-06-22 | Resumed | Morgan Stanley | Overweight |
| Mar-10-22 | Initiated | Daiwa Securities | Outperform |
| Jan-21-22 | Upgrade | DZ Bank | Hold → Buy |
| Jan-03-22 | Reiterated | Bernstein | Mkt Perform |
| Dec-17-21 | Initiated | Goldman | Neutral |
| Dec-16-21 | Reiterated | BMO Capital Markets | Outperform |
| Dec-16-21 | Reiterated | BofA Securities | Buy |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Oct-11-21 | Upgrade | Berenberg | Hold → Buy |
| Sep-29-21 | Upgrade | Citigroup | Neutral → Buy |
| Aug-05-21 | Upgrade | DZ Bank | Hold → Buy |
| Jul-27-21 | Resumed | Truist | Buy |
| Jun-24-21 | Reiterated | Cantor Fitzgerald | Overweight |
| Jan-19-21 | Upgrade | Mizuho | Neutral → Buy |
| Dec-10-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Nov-10-20 | Resumed | Bernstein | Mkt Perform |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Sep-03-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jun-16-20 | Upgrade | Guggenheim | Neutral → Buy |
| Apr-21-20 | Downgrade | UBS | Buy → Neutral |
| Apr-09-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-06-20 | Initiated | Mizuho | Neutral |
| Dec-18-19 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-17-19 | Resumed | BofA/Merrill | Buy |
| May-28-19 | Initiated | Goldman | Buy |
| Apr-24-19 | Upgrade | Edward Jones | Hold → Buy |
| Apr-11-19 | Downgrade | Guggenheim | Buy → Neutral |
| Mar-12-19 | Initiated | JP Morgan | Overweight |
| Jan-23-19 | Initiated | UBS | Buy |
| Nov-26-18 | Downgrade | Citigroup | Buy → Neutral |
| Oct-31-18 | Upgrade | Credit Suisse | Underperform → Neutral |
| Oct-09-18 | Initiated | Guggenheim | Buy |
| Oct-01-18 | Reiterated | SunTrust | Buy |
| Sep-26-18 | Resumed | JP Morgan | Overweight |
View All
Lilly Eli Co Stock (LLY) Latest News
Nvidia, Eli Lilly, Manchester United - TradingView
Eli Lilly and Company ($LLY) Stock: $5B Virginia Facility to Expand Cancer Drug Production - CoinCentral
Eli Lilly (LLY) Receives Downgrade with Reduced Price Target | L - GuruFocus
Novo Aims to Beat Lilly With Something for Everyone in Obesity - Bloomberg.com
Eli Lilly picks Virginia for $5bn drug manufacturing plant - Pharmaceutical Technology
Lilly sees obesity drug leadership beyond US as it leans on consumer-focused strategy - Reuters
Berenberg Downgrades Eli Lilly and Co. to Hold From Buy, Adjusts Price Target to $830 From $970 - MarketScreener
Eli Lilly & Co: Hold Rating Amid Competitive Pressures and Valuation Concerns - TipRanks
AbbVie, Novo get Berenberg boost while Lilly, Merck face downgrades - Investing.com
Eli Lilly (LLY) Falls as Novo Nordisk’s U.S. Survey Shows Its Drug Drowns ‘Food Noise’ - TipRanks
Headlines from across the state: Drug manufacturer Eli Lilly to build plant in Goochland, create 650 permanent jobs; more - Cardinal News
Eli Lilly cautious on using FDA fast-track voucher for weight loss pill - Colorado Springs Gazette
Lilly’s Obesity Pill Will Have Far-Reaching Effect, Doctors Say - Bloomberg.com
Berenberg downgrades Eli Lilly stock rating to Hold on plateauing obesity market - Investing.com
Pharma giant Eli Lilly to build $5B Goochland facility on Markel-owned West Creek site - Richmond BizSense
Eli Lilly unveils plans for $5B manufacturing facility near Richmond, Virginia - MSN
Eli Lilly to invest billions in new US plants - Irish Examiner
News | Eli Lilly picks Virginia for $5 billion manufacturing plant - CoStar
Eli Lilly to develop $5 billion drug manufacturing facility in Goochland - WRIC ABC 8News
Eli Lilly announces a new $5B production plant in Virginia - MSN
Eli Lilly (LLY) Reveals Promising Phase 3 Trial Results for Orfo - GuruFocus
Why Eli Lilly Stock Was a Winner Today - The Motley Fool
Lilly's oral GLP-1, orforglipron, demonstrated meaningful weight loss and cardiometabolic improvements in complete ATTAIN-1 results published in The New England Journal of Medicine - Eli Lilly and Company
Lilly trial shows weight loss with experimental pill flattens over time - Reuters
Lilly weight-loss pill could be FDA-approved by year-end - Reuters
Eli Lilly announces $5 billion pharmaceutical plant in Goochland County - yahoo.com
Drugmaker Eli Lilly to build $5 billion facility in Goochland - Richmond Times-Dispatch
Eli Lilly (LLY) Faces FDA Warning Over Obesity Drug Claims - GuruFocus
Eli Lilly to build $5B plant in Virginia—first of 4 U.S. sites to be named this year - Inside INdiana Business
Citi Maintains a Buy Rating on Eli Lilly and Company (LLY), Retains the $1,190 PT - MSN
Eli Lilly and Company Announces Plans to Build $5 Billion Manufacturing Facility in Virginia - MarketScreener
U.S. FDA sends drug advertising warning letters to Lilly, Novo, Hims - Reuters
FDA Flags Eli Lilly's Weight-Loss Drug Video For Misleading Claims - Benzinga
Bank of America Reiterates Eli Lilly (LLY) Buy on GLP-1 Growth Momentum - MSN
Eli Lilly to invest $5B on Virginia plant amid Trump's pharma tariff threats - Fox Business
Drug manufacturer Eli Lilly to build plant in Goochland, create 650 permanent jobs - yahoo.com
Eli Lilly's new $5B Virginia facility to target cancer, other drugs - upi.com
Eli Lilly plans to build a $5 billion drug making plant in Goochland County: What we know - The Progress Index
Eli Lilly and Company to invest in $5 billion facility in Goochland, Youngkin announces - WRIC ABC 8News
Eli Lilly (LLY) Faces Investor Concerns Over Recent Trial Data - GuruFocus
Eli Lilly To Invest $5 Billion In New Virginia Manufacturing Facility To Support Cancer Drugs Manufacturing - Benzinga
Eli Lilly (LLY) Commits $5B to New Manufacturing Facility in Vir - GuruFocus
Eli Lilly to invest $5 billion in new Virginia plant as pharma braces for tariffs - Reuters
Hershey, Eli Lilly, energy stocks - TradingView
The Book: Eli Lilly issues 40-year notes as weight loss industry booms - The DESK
Eli Lilly Bets $5 Billion On New Virginia Plant - Finimize
Eli Lilly to build $5B manufacturing facility in Virginia - TipRanks
Eli Lilly (LLY) Plans $5 Billion Manufacturing Facility in Virgi - GuruFocus
FDA issues warning letter to Eli Lilly over ZEPBOUND promotional video - StreetInsider
Eli Lilly to invest $5 billion in new Virginia plant as pharma braces for tariffs By Reuters - Investing.com
Lilly announces plans to build $5 billion manufacturing facility in Virginia - Eli Lilly and Company
Lilly Eli Co Stock (LLY) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.53%
0.09%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):